<DOC>
	<DOCNO>NCT02330146</DOCNO>
	<brief_summary>The primary purpose study assess safety profile RCT-01 injection compare placebo injection . This study also measure impact injection tendon structure function symptom Achilles tendinosis . 28 participant select study base health status , current/past medication , ability adhere protocol-related requirement . Prior enter screen phase study , potential study participant least 3 month therapy unilateral , chronic ( symptom &gt; 6 month ) Achilles tendinosis direct certified physiotherapist without clinical response . At first visit provide informed consent participant evaluate study inclusion/exclusion criterion provide blood sample screen assessment ( include virology ) . If suitable study participation , participant provide biopsy scalp RCT-01 prepared . Baseline evaluations participant ' overall health tendinosis , particular , perform day injection . Once baseline assessment complete , tendon treat anesthetized receive ultrasound-guided injection either placebo ( cryomedium ) RCT-01 . All participant return clinic repeat assessment unilateral Achilles tendinosis overall health seven ( 7 ) visit follow 6 month . Participants also complete eccentric training physiotherapy program guidance certify physiotherapist two ( 2 ) month receipt injection . Total duration patient participation approximately eight ( 8 ) month .</brief_summary>
	<brief_title>Safety Efficacy RCT-01 Men Women With Unilateral , Chronic Achilles Tendinosis</brief_title>
	<detailed_description />
	<mesh_term>Tendinopathy</mesh_term>
	<criteria>1 . Male female age 18 65 year good health evidence midsubstance unilateral , chronic Achilles tendinosis confirm ultrasound imaging . 2 . Participant confirmation symptom unilateral chronic Achilles tendinosis least 6 month 3 . Completion least three month physiotherapy treatment Achilles tendinosis study tendon direct certified physiotherapist . 4 . VISAA score less 70 Visit S1 . 5 . Willingness provide write informed consent participation study , attend study visit complete procedure require protocol . 6 . Fluent understand write spoken English language 7 . Females must either postmenopausal least one year , surgically sterile , , childbearing potential , use highlyeffective method birth control study . This method contraception must use least 4 week prior screen ( Visit S1 ) entire duration clinical trial . 1 . Any prior therapeutic injection Achilles tendon study ( e.g. , plateletrich plasma , prolotherapy , dextrose , dry needling , etc ) within 6 month study Visit S1 . 2 . History Achilles tendon surgery ( either tendon ) 3 . Presence enthesopathy insertional tendinopathy tendon low extremity , include Achilles tendon . 4 . Presence medical condition influence low extremity function ( e.g . osteoarthritis , presence peripheral nerve involvement , etc . ) 5 . Presence seronegative arthropathy , diabetes mellitus ( type I II ) , elevate blood sugar , insertional arthropathiespsoriasis , iritis , inflammatory bowel syndrome , sacroiliitis , metabolic syndrome positive test human leukocyte antigen ( HLA ) B 27 . 6 . Any condition , investigator 's opinion would impact participant safety and/or participant 's ability complete study related procedure . ( e.g. , psychiatric illness , drug addiction , alcoholism , etc . ) 7 . Infection hepatitis B C , human immunodeficiency virus ( HIV ) , human Tlymphotropic virus ( HTLV ) syphilis 8 . Participants diagnose cancer without chemotherapy treatment 9 . Women pregnant nursing 10 . Ongoing recent ( within previous 6 month ) participation clinical research study . 11 . Participants diagnose uncontrolled systemic disease 12 . Use medication permit study ( see Excluded Medications ) 13 . Participants currently use active treatment tendinosis physiotherapy ( e.g. , acupuncture , trigger point therapy , chiropractic treatment , glyceryl trinitrate patch ) study within 3 month prior Visit 1 14 . Unresolved litigation insurance claim ( e.g. , Workers Compensation , WorkSafe BC , etc . ) involve Achilles tendinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>